Brenwald N, Andrews J, Bosweli F, Wise R; Interscience Conference on Antimicrobial Agents and Chemotherapy.

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1996 Sep 15-18; 109 (abstract no. F54).

City Hospital NHS Trust, Birmingham, United Kingdom.

The in vitro activity of CG5501 (CG) a new fluoroquinolone was compared with that of ciprofloxacin (CIP), sparfloxacin (SPAR) and trovafloxacin (TRO) against 854 recent bacterial isolates. The activity of CG was also tested against 4 strains of chlamydia and 5 strains of Mycobacterium tuberculosis. Against the enterobacteriaceae CG was overall similar to SPAR and TRO, but 2-8 fold less active than CIP. Ninety three percent of the enterobacteriaceae strains were inhibited by less than or equal to 0.5 micrograms/ml of CG. Staphylococcus aureus (including MRSA) was more susceptible to CG and SPAR (MIC(90) 0.25 micrograms/ml) than CIP (MIC(90) 2.0 micrograms/ml). Against MRSA CG was 2-4 fold and 16-32 fold more active than SPAR and CIP respectively. CG was active against the respiratory pathogens Strept. pneumoniae (MIC(90) 0.5 micrograms/ml), H. influenzae (MIC(90) 0.015 micrograms/ml) and M. catarrhalis (MIC(90) 0.06 micrograms/ml). Against Bacteriodes fragilis CG had similar activity to TRO (MIC(90) 0.25 micrograms/ml), but was more active than SPAR and CIP. All 4 strains of chlamydia were susceptible to CG (MIC 0.06-0.12 micrograms/ml) the activity being similar to that of doxycycline. Against Mycobacterium tuberculosis CG (MIC 0.12-0.5 micrograms/ml) was 2-4 fold more active than CIP.

Publication Types:

• Meeting Abstracts

Keywords:

• Chlamydia
• Ciprofloxacin
• Doxycycline
• Enterobacteriaceae
• Fluoroquinolones
• In Vitro
• Microbial Sensitivity Tests
• Mycobacterium tuberculosis
• Naphthyridines
• sparfloxacin
• trovafloxacin

Other ID:

• 98927671

UI: 102234845

From Meeting Abstracts